TFA
LFCR icon

Transamerica Financial Advisors’s Lifecore Biomedical LFCR Stock Holding History

Transamerica Financial Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267 Hold
51
– – ﹤0.01% 1816
2026
Q1 		$189 Buy
+51
New +$352 ﹤0.01% 1643

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Transamerica Financial Advisors's LFCR Position: Q2 2026 in Review

Transamerica Financial Advisors held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 51 shares worth $267. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Transamerica Financial Advisors first reported a position in LFCR in Q1 2026 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Transamerica Financial Advisors held 51 shares of Lifecore Biomedical worth $267 as of Q2 2026.
  • Transamerica Financial Advisors left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1816 holding.
  • Transamerica Financial Advisors first reported a position in Lifecore Biomedical in Q1 2026 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.